Promising long-term safety and effectiveness results from PAD population with extremely complex SFA disease
PQ Bypass, Inc, a medical device pioneer bringing new advancements to the treatment of complex peripheral artery disease (PAD), announces promising long-term safety and effectiveness results from 24-month follow-up data from the DETOUR1 Clinical Study, including a 79% primary patency, with 82% of patients maintaining freedom from major adverse events at 2 years post-procedure. The DETOUR1 trial is the first-in-man trial of the FDA-designated Breakthrough Device, The Detour System, evaluating the safety and effectiveness of the novel procedure and device system for treating long, complex lesions in the superficial femoral artery (SFA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201113005130/en/
An illustration of a completed Detour Procedure (Graphic: Business Wire)
The data were released as one of the “10 Highly Anticipated Late-Breaking Clinical Trial Releases” during the VIVA 2020 Virtual Conference. The data